🇺🇸 FDA
Patent

US 11472881

Single-domain antibodies and variants thereof against CTLA-4

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11472881 (Single-domain antibodies and variants thereof against CTLA-4) held by Nanjing Legend Biotech Co., Ltd expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nanjing Legend Biotech Co., Ltd
Grant date
Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K47/65